Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Titel:
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Auteur:
Geyer Jr., C.E. Garber, J.E. Gelber, R.D. Yothers, G. Taboada, M. Ross, L. Rastogi, P. Cui, K. Arahmani, A. Aktan, G. Armstrong, A.C. Arnedos, M. Balmaña, J. Bergh, J. Bliss, J. Delaloge, S. Domchek, S.M. Eisen, A. Elsafy, F. Fein, L.E. Fielding, A. Ford, J.M. Friedman, S. Gelmon, K.A. Gianni, L. Gnant, M. Hollingsworth, S.J. Im, S.-A. Jager, A. Jóhannsson, Ó. Þ Lakhani, S.R. Janni, W. Linderholm, B. Liu, T.-W. Loman, N. Korde, L. Loibl, S. Lucas, P.C. Marmé, F. Martinez de Dueñas, E. McConnell, R. Phillips, K.-A. Piccart, M. Rossi, G. Schmutzler, R. Senkus, E. Shao, Z. Sharma, P. Singer, C.F. Španić, T. Stickeler, E. Toi, M. Traina, T.A. Viale, G. Zoppoli, G. Park, Y.H. Yerushalmi, R. Yang, H. Pang, D. Jung, K.H. Mailliez, A. Fan, Z. Tennevet, I. Zhang, J. Nagy, T. Sonke, G.S. Sun, Q. Parton, M. Colleoni, M.A. Schmidt, M. Brufsky, A.M. Razaq, W. Kaufman, B. Cameron, D. Campbell, C. Tutt, A.N.J.